Axsome Therapeutics (AXSM)
(Delayed Data from NSDQ)
$95.84 USD
+1.52 (1.61%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $95.78 -0.06 (-0.06%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Income Statements
Fiscal Year end for Axsome Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 271 | 50 | 0 | 0 | 0 |
Cost Of Goods | 26 | 5 | 0 | 0 | 0 |
Gross Profit | 245 | 45 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 476 | 225 | 125 | 99 | 67 |
Income After Depreciation & Amortization | -232 | -180 | -125 | -99 | -67 |
Non-Operating Income | 0 | 0 | 0 | -1 | 0 |
Interest Expense | 6 | 7 | 6 | 3 | 1 |
Pretax Income | -238 | -187 | -130 | -103 | -68 |
Income Taxes | 1 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -239 | -187 | -130 | -103 | -68 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -239 | -187 | -130 | -103 | -68 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -222 | -173 | -122 | -98 | -67 |
Depreciation & Amortization (Cash Flow) | 9 | 7 | 2 | 1 | 1 |
Income After Depreciation & Amortization | -232 | -180 | -125 | -99 | -67 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 45.43 | 40.67 | 37.62 | 37.21 | 34.02 |
Diluted EPS Before Non-Recurring Items | -2.67 | -4.42 | -3.47 | -2.74 | -2.01 |
Diluted Net EPS (GAAP) | -5.27 | -4.60 | -3.47 | -2.77 | -2.01 |
Fiscal Year end for Axsome Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 87.17 | 75.00 | 71.53 | 57.79 | 46.70 |
Cost Of Goods | 8.06 | 6.30 | 7.38 | 6.53 | 4.60 |
Gross Profit | 79.11 | 68.70 | 64.15 | 51.26 | 42.10 |
SG&A, R&D, and Dept/Amort Expenses | 157.15 | 135.98 | 162.43 | 113.39 | 107.16 |
Income After SG&A, R&D, and Dept/Amort Expenses | -78.04 | -67.28 | -98.28 | -62.13 | -65.06 |
Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Interest Expense | 1.30 | 1.08 | 0.70 | 0.76 | 2.73 |
Pretax Income | -79.35 | -68.36 | -98.98 | -62.88 | -67.79 |
Income Taxes | 0.00 | 0.00 | -0.32 | -0.68 | -0.62 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -79.35 | -68.36 | -98.65 | -62.20 | -67.17 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -79.35 | -68.36 | -98.65 | -62.20 | -67.17 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 47.57 | 47.39 | 47.33 | 47.12 | 43.67 |
Diluted EPS Before Non-Recurring Items | -1.24 | -1.09 | -0.73 | -1.32 | -1.00 |
Diluted Net EPS (GAAP) | -1.67 | -1.44 | -2.15 | -1.32 | -1.54 |